Skip to main content
SpringerLink
Log in

CXCR4-Directed Endoradiotherapy as New Treatment Option in Advanced Multiple Myeloma

  • Chapter
  • First Online:
Clinical Applications of Nuclear Medicine Targeted Therapy

  • 974 Accesses

Abstract

Multiple myeloma (MM) accounts for approximately 1% of all cancers and around 10% of hematological malignancies. Although various novel drugs and treatment options including proteasome inhibitors, immunomodulators, antibodies, or the implementation of autologous and allogeneic stem cell transplantation have improved overall survival over the last decades, MM essentially remains an incurable disease. In relapsed/refractory disease, even the most intense treatment regimens frequently fail to efficiently reduce the tumor burden, and patients eventually succumb to their disease.

Given the paramount importance of C-X-C chemokine receptor CXCR4 for both multiple myeloma and bone marrow microenvironment, development of radiolabeled receptor ligands for both CXCR4-directed imaging and therapy has opened new exciting opportunities in the field of radionuclide therapies. Endoradiotherapy can be safely performed as part of the conditioning regimen prior to autologous or allogeneic stem cell transplantation. First experience has hinted at high tumor cell kill in even very advanced MM including extramedullary disease. Further prospective studies to evaluate the efficacy in earlier disease stages are about to be initiated and will also provide further evidence on synergistic multimodality treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  PubMed  Google Scholar 

  2. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998;426:271–8.

    Article  CAS  PubMed  Google Scholar 

  3. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–7.

    Article  CAS  PubMed  Google Scholar 

  4. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49:219–30.

    Article  CAS  PubMed  Google Scholar 

  5. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–8.

    Article  CAS  PubMed  Google Scholar 

  6. Loetscher P, Moser B, Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol. 2000;74:127–80.

    Article  CAS  PubMed  Google Scholar 

  7. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–7.

    Article  CAS  PubMed  Google Scholar 

  8. Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6:5022–40.

    PubMed  Google Scholar 

  9. Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica. 2006;91:200–6.

    CAS  PubMed  Google Scholar 

  10. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

    Article  CAS  PubMed  Google Scholar 

  11. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35:816–26.

    Article  CAS  PubMed  Google Scholar 

  12. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109:2708–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1:539–44.

    Article  CAS  PubMed  Google Scholar 

  15. Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5:11283–96.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011;6:1789–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gourni E, Demmer O, Schottelius M, D’Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803–10.

    Article  CAS  PubMed  Google Scholar 

  18. Hartimath SV, Domanska UM, Walenkamp AM, Rudi AJOD, de Vries EF. [(9)(9)mTc]O(2)-AMD3100 as a SPECT tracer for CXCR4 receptor imaging. Nucl Med Biol. 2013;40:507–17.

    Article  CAS  PubMed  Google Scholar 

  19. Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101:932–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, et al. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57:741–6.

    Article  CAS  PubMed  Google Scholar 

  21. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016;41:515.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lapa C, Luckerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience. Oncotarget. 2016;7:9288.

    PubMed  PubMed Central  Google Scholar 

  23. Lapa C, Reiter T, Werner RA, Ertl G, Wester HJ, Buck AK, et al. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression after myocardial infarction. JACC Cardiovasc Imaging. 2015;8:1466–8.

    Article  PubMed  Google Scholar 

  24. Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, Herrmann K, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;7:205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lapa C, Schirbel A, Samnick S, Luckerath K, Kortum KM, Knop S, et al. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. Eur J Nucl Med Mol Imaging. 2017;44:1097–8.

    Article  PubMed  Google Scholar 

  27. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hanscheid H, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57:248–51.

    Article  CAS  PubMed  Google Scholar 

  28. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.

    Article  CAS  PubMed  Google Scholar 

  31. Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, Germany

    Constantin Lapa

  2. Department of Internal Medicine II, Universitätsklinikum Würzburg, Würzburg, Germany

    K. Martin Kortüm

  3. Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany

    Ken Herrmann

Authors
  1. Constantin Lapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Martin Kortüm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Herrmann .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  2. Nuclear Medicine Therapy and Endocrinology, Istituto Nazionale dei Tumori, Milano, Italy

    Ettore Seregni

  3. Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy

    Laura Evangelista

  4. Nuclear Medicine Division, Istituto Nazionale dei Tumori, Milano, Italy

    Carlo Chiesa

  5. Nuclear Medicine, Humanitas Research Hospital, Rozzano, Milano, Italy

    Arturo Chiti

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lapa, C., Martin Kortüm, K., Herrmann, K. (2018). CXCR4-Directed Endoradiotherapy as New Treatment Option in Advanced Multiple Myeloma. In: Bombardieri, E., Seregni, E., Evangelista, L., Chiesa, C., Chiti, A. (eds) Clinical Applications of Nuclear Medicine Targeted Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-63067-0_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63067-0_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63066-3

  • Online ISBN: 978-3-319-63067-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation